Approach

Our Approach

At GeneSys, we specialize in making biosimilars with a patient-first approach, striving to solve critical issues in patient access to essential medicines. We take a comprehensive approach from clonal development to clinical development. Our emphasis is on delivering a biosimilar through an accelerated regulatory pathway heavily built on process, analytical and regulatory sciences.

We take integrity & totality approach in bridging the gap between accessibility, affordability, and unmet basic medical need, without compromising on quality. For stakeholders of GeneSys, it has been an investment for the future of people living with diabetes. For all of us, it is as personal as it gets. We are constantly thinking to be differently in all areas so we can provide better access to the insulin-dependent patients and communities we are going to serve.

Committed to Quality and Meaningful Affordability

Every decision that we make at GeneSys is founded in our passion to make a meaningful difference (not just promises) and is profoundly built on providing high quality medicines with most affordable and responsible pricing.

We take our commitment with great responsibility and make all serious efforts to deliver our products that transform lives across the globe, eradicating as many as barriers in reaching out to as many as diabetic patients. Our operational principle is that “No one should be left behind without access” – this drives us to provide transformational impact in the diabetes segment that we are operating.

Strong Partnerships

At GeneSys, our passion for bringing accessible and affordable insulins to cover as many as diabetic patients in need essentially drives our partnering strategy. As one of the fastest growing biotechnology companies from India, our strong partnership such with Civica Rx (www.civicarx.org) in the US is enabling us to lead in the insulin segment (www.civicainsulin.org).

With our global strategic focus on building a balanced insulin pipeline and willingness to reaching reach out to the last patient that needs insulin, we’re actively looking for partnerships where we can achieve goals together across different geographies.